苯丙醇胺事件的启示

目的：使医药企业从苯丙醇胺（PPA）事件中吸取教训。方法：阐述生产企业－中美史克公司在此事件中的巨大损失，分析事件的发生并非突然，事先有其临床研究报告及各国发布的禁令或警诫。结果：如果及早掌握这些信息，损失可以减少。结论：必须加强药品上市后的监测工作，重视药物流行病学研究；医药企业必须加强信息工作。

Lessons of the Ban onPhenylpropanolamine(PPA)

To help pharmaceutical companies absorb lessons from the Ban on PPA, the article analyses the behavior of SinoUS Smith Kline & French, which led to great loss after the Ban of an PPA by SDA of China. It points out that the Ban of PPA did not come unexpectedly. Before the Ban many clinical reports had been released and the authorities of some countries had already introduced ban on PPA or issued warnings on the possible danger of PPA. If the company in question had taken timely measures to keep track of the information, the loss could have been minimized, It is concluded that the pharmaceutical companies should step up their effort for the monitoring and following-up of their products after introduction of their durgs to markets and attach importance to the study of pharmacoepidemioloy. Pharmaceutical companies should put emphasis on the collection of information.